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Markers of myocyte necrosis such as cardiac troponin or creatine kinase-myocardial band are
invaluable tools for risk stratification among patients presenting with acute coronary
syndromes (ACS). Nonetheless, many patients without any evidence of myocyte necrosis may
be at high risk for recurrent ischemic events. In consideration of the important role that
inflammatory processes play in determining plaque stability, recent work has focused on
whether plasma markers of inflammation may help improve risk stratification. Of these
markers, C-reactive protein (CRP) has been the most widely studied, and there is now robust
evidence that CRP is a strong predictor of cardiovascular risk among apparently healthy
individuals, patients undergoing elective revascularization procedures, and patients presenting
with ACS. Moreover, even among patients with troponin-negative ACS, elevated levels of
CRP are predictive of future risk. Other, more upstream markers of the inflammatory cascade,
such as interleukin (IL)-6, have also been found to be predictive of recurrent vascular
instability. A recent report from the second FRagmin during InStability in Coronary artery
disease trial investigators suggests that elevated levels of an inflammatory marker such as IL-6
may indicate which patients may benefit most from an early invasive strategy. Other
inflammatory markers currently under investigation include lipoprotein-associated phospho-
lipase A2, myeloperoxidase, and pregnancy-associated plasma protein A. Of all these novel
markers, CRP appears to meet most of the criteria required for potential clinical application.
Furthermore, the benefits of lifestyle modification and drug therapy with aspirin or statins
may be most marked among those with elevated CRP levels. (J Am Coll Cardiol 2003;41:
37S–42S) © 2003 by the American College of Cardiology Foundation
Approximately 1.4 million patients with acute coronary
syndromes (ACS) without ST-segment elevation are admit-
ted to hospital annually in the U.S. (1). Markers of myocyte
necrosis such as creatine kinase-myocardial band (CK-MB)
and cardiac troponin are invaluable diagnostic tools for such
patients and are routinely used for risk stratification. How-
ever, even troponin, a highly specific marker of cardiac
myocyte necrosis, has relatively low diagnostic sensitivity for
ACS, with only 22% to 50% of patients with unstable
angina having positive troponin (I or T) tests (2–5). More-
over, many patients with troponin-negative ACS who have
vulnerable coronary plaques remain at high risk for future
ischemic events. Thus, an additional test to improve upon
risk stratification based on markers of myocyte necrosis
alone could prove a valuable aid in clinical practice.
INFLAMMATORY MARKERS: C-REACTIVE PROTEIN
Pathophysiology. The past decade has witnessed an in-
creasing recognition that inflammatory mechanisms play a
central role in the pathogenesis of atherosclerosis and its
complications (6). Recently, attention has focused on the
potential role of plasma markers of inflammation as risk
predictors among those at risk for cardiovascular events (7).
Of these potential markers, C-reactive protein (CRP) has
been the most extensively studied. Produced in the liver in
response to interleukin (IL)-6, CRP is an acute phase
reactant that serves as a pattern recognition molecule in the
innate immune system. It was initially thought of as a
downstream bystander marker of vascular inflammation, but
recent data suggest that CRP may play an active role in
atherogenesis. C-reactive protein opsonization of low-
density lipoprotein (LDL) mediates LDL uptake by mac-
rophages (8), and CRP also stimulates monocyte release of
pro-inflammatory cytokines such as IL-1b, IL-6, and tumor
necrosis factor-alpha (9). Furthermore, CRP mediates
monocyte chemotactic protein-1 induction in endothelial
cells (10) and causes expression of intercellular adhesion
molecule-1 and vascular cellular adhesion molecule-1 by
endothelial cells (11). Recent data have shown that CRP
co-localizes with the membrane attack complex in early
atheromatous lesions, and CRP, complement proteins, and
their messenger ribonucleic acid are all substantially upregu-
lated in atheromatous plaque (12).
CRP as a predictor of risk. Numerous large-scale epide-
miological studies among apparently healthy men and
women have found that CRP is a strong independent
predictor of future cardiovascular risk (13–22). In the setting
of ACS, a landmark study by Liuzzo et al. (23) showed that
patients presenting with unstable angina who had elevated
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plasma levels of CRP (3 mg/l) and serum amyloid A had
a higher rate of death, acute myocardial infarction (MI), and
need for revascularization compared with patients without
elevated levels (Table 1).
The Thrombolysis In Myocardial Infarction (TIMI)
investigators have since shown that the increased risk
associated with high CRP levels may be evident as early as
14 days after presentation with an ACS (24). The Chimeric
c7E3 AntiPlatelet Therapy in Unstable angina Refractory to
standard treatment (CAPTURE) trial investigators found
that, although only troponin T was predictive in the initial
72-h period, both CRP and troponin T were independent
predictors of risk at six months (25), while the FRagmin
during InStability in Coronary artery disease (FRISC)
investigators reported that the risk associated with elevated
CRP levels at the time of index event continues to increase
for several years (26). In each of the above studies, the
predictive value of CRP was independent of, and additive
to, troponin (Table 1). Most importantly, CRP has been
found to have prognostic value among patients without
evidence of myocyte necrosis; specifically, even among
patients with negative troponin T, an elevated CRP is
predictive of future adverse events (24–26). Recent data also
confirm that CRP is a strong independent predictor of
short-term and long-term mortality among patients with
ACS who are treated with very early revascularization (27).
The exact source of elevated CRP levels among patients
with unstable coronary syndromes remains unclear. Data
suggest that plaque rupture per se may not be the cause but,
rather, that elevated CRP levels may be a marker of the
hyper-responsiveness of the inflammatory system to even
small stimuli. The CRP levels do not change after balloon
angioplasty in patients with stable or unstable angina who
have normal pre-procedural levels, but they do increase after
angioplasty in unstable patients with elevated CRP at
baseline (28). Moreover, even diagnostic angiography with-
out intervention caused an increase in CRP levels among
patients with elevated levels at baseline.
Other inflammatory markers. Further data regarding up-
stream mediators of CRP production suggest that this
pathway may reflect inflammatory processes that convey
increased cardiovascular risk. Elevated levels of IL-1 recep-
tor antagonist and IL-6 at 48 h after presentation are
associated with an adverse in-hospital prognosis among
patients with ACS, even without a rise in troponin T (29).
A recent report from the FRISC II study group has found
that circulating levels of IL-6 are a strong independent
marker of increased mortality among patients with unstable
coronary artery disease (CAD) and may be useful in
directing subsequent care (30). For example, randomization
to an early invasive strategy led to a 65% relative reduction
in 12-month mortality among patients with elevated IL-6
levels. By contrast, among those with low IL-6 levels, an
early invasive strategy did not confer any significant benefit
over a non-invasive strategy. Furthermore, among patients
randomized to the non-invasive arm, the risk associated
with elevated IL-6 levels was markedly attenuated if they
were assigned to therapy with dalteparin rather than placebo
(30). Similar data were observed for CRP. Thus, the use of
an inflammatory marker for risk stratification appears to
identify patients at high risk for future events, but most
importantly, it appears to identify individuals who might
benefit most from targeted interventional or intensive med-
ical therapy.
Other novel inflammatory markers have been studied in
cardiovascular risk prediction. Lipoprotein-associated phos-
pholipase A2 (Lp-PLA2) circulates in association with
LDL-cholesterol and may contribute to atherogenesis by
hydrolyzing oxidized phospholipids into pro-atherogenic
fragments and by generating lysolecithin, which has pro-
inflammatory properties. The West of Scotland study group
Abbreviations and Acronyms
ACS  acute coronary syndrome(s)
BNP  B-type natriuretic peptide
CAD  coronary artery disease
CK-MB  creatine kinase-myocardial band
CRP  C-reactive protein
IL  interleukin
LDL  low-density lipoprotein
Lp-PLA2  lipoprotein-associated phospholipase A2
MI  myocardial infarction
MPO  myeloperoxidase
PAPP-A  pregnancy-associated plasma protein A
Table 1. CRP and Cardiovascular Risk in ACS: Results From Recent Trials
Study/Trial Results
Liuzzo et al. (23)* Increased rate of death, MI, and revascularization in patients with unstable angina
and CRP 3 mg/l plus elevated serum amyloid A.
TIMI IIa substudy (24)* Increased risk associated with higher CRP levels, evident as early as 14 days after
ACS.
CAPTURE (25)* CRP is an independent predictor of increased risk at 6 months.
FRISC (26)* Increased risk associated with higher CRP levels at index event.
Mueller et al. (27) CRP predictive of short- and long-term mortality among ACS patients treated
with early revascularization.
*The predictive value of CRP was independent of, and additive to, that of troponin.
ACS  acute coronary syndromes; CAPTURE  Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to
standard treatment; CRP  C-reactive protein; FRISC  FRagmin during InStability in Coronary artery disease; MI 
myocardial infarction; TIMI  Thrombolysis In Myocardial Infarction.
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reported that baseline levels of Lp-PLA2 were a strong
independent predictor of risk for incident coronary heart
disease in a cohort of high-risk hyperlipidemic men (31).
Among a lower-risk cohort of normocholesterolemic
women, baseline levels of Lp-PLA2 were also higher among
cases than controls (32). However, in adjusted analyses,
baseline levels of Lp-PLA2 were not a significant predictor
of future cardiovascular risk, while CRP remained a strong
predictor (32). Lp-PLA2 levels are highly correlated with
LDL-cholesterol, which may in part explain these different
results. The predictive value of Lp-PLA2 among patients
with ACS is currently unknown.
Myeloperoxidase (MPO) levels may be elevated among
individuals with CAD (33). Myeloperoxidase is an enzyme
secreted by a variety of inflammatory cells, including acti-
vated neutrophils, monocytes, and certain tissue macro-
phages, such as those found in atherosclerotic plaque. The
enzyme is not released until leukocyte activation and de-
granulation. Myeloperoxidase may convert LDL into a
high-uptake form for macrophages, leading to foam cell
formation, and may also deplete nitric oxide, contributing to
endothelial dysfunction. In a recent case-control study,
increasing levels of leukocyte-MPO and blood-MPO were
significant predictors of the risk for CAD, such that after
adjustment for white blood cell count and Framingham risk
score, individuals in the highest quartile of blood-MPO had
a 20-fold higher risk of CAD than individuals in the lowest
quartile (33). Prospective studies are thus needed to test this
interesting hypothesis directly.
Recent ACS data have also been presented for
pregnancy-associated plasma protein A (PAPP-A) (34).
This zinc-binding metalloproteinase enzyme is a specific
activator of insulin-like growth factor I, a mediator of
atherosclerosis. Among eight patients who died suddenly
from cardiac causes, PAPP-A was abundantly expressed in
ruptured and eroded unstable plaques, but PAPP-A was
absent or minimally expressed in stable plaques. In plaques
with large lipid cores and cap rupture, staining for PAPP-A
revealed that the enzyme occurred mostly in the inflamma-
tory shoulder region. In a small case-control study, circu-
lating levels of PAPP-A were higher among patients with
unstable angina or acute MI than among patients with
stable angina and controls (34). Levels of CRP were also
higher among those with acute MI and unstable angina than
those with stable angina. Among patients with ACS, levels
of PAPP-A and CRP were highly correlated (r 0.61), but
there was no association between PAPP-A and CK-MB
(r 0.07) or troponin I (r 0.1). As with MPO, these data
require assessment in larger cohorts.
Non-inflammatory markers. de Lemos et al. (35) have
also recently reported data regarding the potential prognos-
tic utility of B-type natriuretic peptide (BNP) among
patients with ACS in the Orbofiban in Patients with
Unstable coronary Syndromes (OPUS)-TIMI 16 study.
Unlike inflammatory markers, BNP is a neurohormone
synthesized in ventricular myocardium and released in
response to pressure overload and ventricular dilation. Base-
line levels of BNP, drawn on average 40 h after the onset of
ischemic symptoms, correlated with the risk of death, heart
failure, and MI at 30 days and 10 months. This association
was significant across the full spectrum of ACS, including
patients presenting with ST-segment elevation MI, MI
without ST elevation, and unstable angina. Although it was
statistically significant, the correlation between BNP and
CRP was weak (r  0.2; p  0.001). After being adjusted
for other independent predictors of risk of death, including
the presence or absence of heart failure in patients, the odds
ratio for death at 10 months for the top quartile of BNP
compared with the lowest was 5.8, BNP also remained a
significant predictor of death when analyses were restricted
to an investigation of the presence or absence of elevated
troponin levels. Non-CRP inflammatory and non-
inflammatory biomarker results are summarized in Table 2.
Clinical utility. Three major questions must be answered
before routine clinical application of inflammatory markers
is advocated (36,37). First, does the marker independently
predict risk beyond conventional tools? Second, are specific
therapies available to reduce levels of the inflammatory
Table 2. Other Novel Inflammatory and Non-Inflammatory Biomarkers of Increased
Cardiovascular Risk
Inflammatory Biomarker Predictive Value
IL-6 Associated with adverse in-hospital prognosis in ACS patients (29).
Independent marker of increased mortality in unstable CAD (30).
Associated risk attenuated with dalteparin therapy (30).
Lp-PLA2 Independent predictor of risk for heart disease in a high-risk male
population (31).
MPO Significant predictor of CAD risk in case control studies.
PAPP-A Abundantly expressed in unstable plaques and elevated in unstable angina
and MI patients; absent or minimally expressed in stable plaques or in
stable angina patients or controls (34).
Non-inflammatory biomarker
BNP Baseline levels correlate with risk of death, heart failure, MI in ACS (35).
ACS  acute coronary syndrome; BNP  B-type natriuretic peptide; CAD  coronary artery disease; IL  interleukin;
Lp-PLA2  lipoprotein-associated phospholipase A2, MI  myocardial infarction; MPO  myeloperoxidase; PAPP-A 
pregnancy-associated plasma protein A.
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marker, and third, do therapies that lower plasma levels of
inflammatory markers also reduce cardiovascular risk? To
this list could also be added the need for a widely available
reliable biochemical assay.
Of the inflammatory markers discussed in the previous
text, CRP currently meets most, if not all, of these criteria.
C-reactive protein has been shown to predict risk in a wide
variety of clinical settings; it has incremental value in
addition to standard lipid screening for primary prevention
(18,19,38) and in addition to cardiac troponin testing
among patients with ACS (24–26). Furthermore, a recent
analysis by Chew et al. (39) shows that CRP predicts the
risk of death or MI at 30 days among patients undergoing
percutaneous coronary intervention. In this setting, the risk
associated with elevated CRP was independent of, but
additive to, the effect of an increased American College of
Cardiology/American Heart Association lesion score.
C-reactive protein levels are higher among smokers,
diabetics, and obese subjects. Adipose tissue is a potent
source of IL-6, the main hepatic stimulus for CRP produc-
tion. Thus, intensification of dietary measures and exercise
programs would seem to be appropriate for these individu-
als. Statin therapy may have powerful anti-inflammatory
effects (40), and in recent clinical studies, statin therapy has
been shown to lower CRP levels, an effect that is indepen-
dent of lipid lowering (19,41–44). Recent data suggest that
baseline levels of CRP and IL-6 are strong independent
predictors of the risk of developing type II diabetes (45). In
this regard, intriguing data from the West of Scotland study
suggest that pravastatin therapy, compared with placebo,
reduced the risk of development of type II diabetes (46).
Further data suggest that the benefits of statin therapy
may be greatest among those with elevated CRP levels,
either among post-MI patients (47) or in the primary
prevention setting (19). In the Cholesterol And Recurrent
Events (CARE) trial population, patients with persistent
low-grade vascular inflammation, as evidenced by high CRP
and serum amyloid A levels, were at increased risk of
recurrent events. Randomization to pravastatin therapy
prevented 54% of recurrent events among those with per-
sistent inflammation, compared with 25% among those
without (47). Similarly, in the primary prevention Air
Force/Texas Coronary Atherosclerosis Prevention Study
(AFCAPS/TexCAPS), individuals with low LDL levels
(149 mg/dl) but high CRP levels (0.16 mg/dl) were at
high risk for future cardiovascular events, and they derived
substantial benefit from lovastatin therapy (relative risk
compared with placebo  0.58; 95% confidence interval,
0.34 to 0.98) (19).
Current clinical practice should not be based on these
post-hoc analyses (16,43), and there are currently no pro-
spective data that prove that lowering CRP decreases
cardiovascular events or improves survival, or that establish
defined targets for treatment. Thus, although substantial
gains may be made by targeting statin therapy at those with
heightened vascular inflammation (48), prospective ran-
domized trials to test these hypotheses directly are needed.
The effect of aspirin on CRP levels is controversial
(49,50), but the benefit of aspirin therapy in preventing
future MI appears to be greatest among those with elevated
CRP levels (16). As noted above, data from the FRISC-II
study suggest that the benefits of an early invasive approach
may be greatest among those with evidence of a heightened
inflammatory response (30). In the absence of an elevated
inflammatory response, a less invasive approach may prove
equally effective. Again, prospective randomized studies are
required to test these hypotheses directly. The possibility of
novel anti-inflammatory interventions targeted at specific
mediators of vascular inflammation is also appealing.
The optimal cutoff point for defining high CRP levels
among patients with ACS remains to be determined. The
CAPTURE group found that a threshold of 10 mg/l
maximized the predictive value of CRP (25). Several other
investigators have used a cutoff point of 3 mg/l for patients
with ACS, while the reference ranges for primary preven-
tion populations are lower (16,18,19). The precise cause of
these different thresholds remains unclear, but it is probably
related to heightened vascular inflammation at the time of
presentation with ACS.
CONCLUSIONS
In summary, the use of CRP and other novel inflammatory
markers may significantly add to our ability to correctly
identify patients presenting with ACS who are at high risk
for future cardiovascular events. The predictive value of
CRP appears to be independent of, and in addition to,
troponin. Individuals with evidence of heightened inflam-
mation may benefit most from an aggressive modification of
lifestyle and an intensification of proven preventive thera-
pies such as aspirin and statins. Moreover, the benefits of an
early invasive strategy may also be greatest among those
with elevated levels of inflammatory biomarkers.
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